Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials
- 30 June 2012
- journal article
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (6), 1607-1616
- https://doi.org/10.1093/annonc/mdr491
Abstract
Neoadjuvant chemotherapy improves outcome in osteosarcoma. Determination of optimum regimens for survival, toxicity and prognostic factors requires randomised controlled trials to be conducted. Between 1983 and 2002, the European Osteosarcoma Intergroup recruited 1067 patients with localised extremity osteosarcoma to three randomised controlled trials. Standard treatment in each was doxorubicin 75 mg/m(2) and cisplatin 100 mg/m(2). Comparators were addition of methotrexate (BO02/80831), a multidrug regimen (BO03/80861) and a dose-intense schedule (BO06/80931). Standard survival analysis methods were used to identify prognostic factors, temporal and other influences on outcome. Five- and 10-year survival were 56% (95% confidence interval 53% to 59%) and 52%, respectively (49% to 55%), with no difference between trials or treatment arms. Median follow-up was 9.4 years. Age range was 3-40 years (median 15). Limb salvage was achieved in 69%. Five hundred and thirty-three patients received the standard arm, 79% completing treatment. Good histological response to preoperative chemotherapy, distal tumour location (all sites other than proximal humerus/femur) and female gender were associated with improved survival. Localised osteosarcoma will be cured in 50% of patients with cisplatin and doxorubicin. Large randomised trials can be conducted in this rare cancer. Failure to improve survival over 20 years argues for concerted collaborative international efforts to identify and rapidly test new treatments.Keywords
Funding Information
- UK Medical Research Council
- National Institute of Health Research Comprehensive Biomedical Research Centre programme
This publication has 32 references indexed in Scilit:
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?European Journal of Cancer, 2011
- Review of Adherence-Related Issues in Adolescents and Young Adults With CancerJournal of Clinical Oncology, 2010
- The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocolsAnnals Of Oncology, 2010
- The epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002BMC Cancer, 2010
- Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma IntergroupEuropean Journal of Cancer, 2002
- ErbB2 expression is correlated with increased survival of patients with osteosarcomaCancer, 2002
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002
- The effect of local recurrence on survival in resected osteosarcomaEuropean Journal of Cancer, 2001
- Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity OsteosarcomaJournal of Clinical Oncology, 2000
- Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated ReportJournal of Clinical Oncology, 2000